Abstract: |
The majority of peripheral CD4+ T lymphocytes proliferate in vitro in response to anti-CD3 in presence of autologous APC. The present study describes a subpopulation of CD4+ T cells that cannot be activated and progress into cell cycle by stimulation with anti-CD3 plus APC or with mitogenic combinations of anti-CD2. The in vitro responses of these anti-CD3-unresponsive CD4+ T cells were investigated with a panel of mAb to CD2, CD3, and CD28, and found to be similar to those previously observed for mature thymocytes: only the combination of anti-CD2 plus anti-CD28 produced cell proliferation. Anti-CD3-unresponsive T cells were CD45RA+, but represented only 14 to 22% of the CD4+, CD45RA+ T cell population. Activation with anti-CD2 plus anti-CD28 mAb resulted in major changes in the cell surface phenotype and functional properties: a loss of CD45RA+ occurred and an increased expression of CD45RO, CD29, and CD58 (LFA3), as well as a gain in responsiveness to anti-CD3 and anti-CD2. This change in CD45 phenotype from CD45RA to CD45RO occurs in both the anti-CD3-responsive and in the anti-CD3-unresponsive subsets of the CD45RA+, CD4+ cells after cell proliferation. The anti-CD3-unresponsive subset may represent a pool of not yet fully differentiated peripheral T cells. The acquisition of anti-CD3 responsiveness could occur as a consequence of Ag priming or by an Ag-independent mechanism. Involvement of the CD28 Ag in this process is suggested from the present study. |
Keywords: |
nonhuman; flow cytometry; cd3 antigen; lymphocyte proliferation; antigens, cd3; animal cell; mouse; phenotype; cell cycle; lymphocyte activation; antibodies, monoclonal; cell culture; receptors, antigen, t-cell; cd4-positive t-lymphocytes; recombinant proteins; cd4 antigen; antigens, cd; antigen-presenting cells; antigens, cd28; interleukin-2; in vitro; antigens, differentiation; interleukin-1; antigens, cd45; antigens, differentiation, t-lymphocyte; histocompatibility antigens; human; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; antigens, cd58
|